RSS Feeds
C-Reactive Protein and Risk for Colorectal Cancer
- Shumin M. Zhang, MD, ScD; and
- Paul M Ridker, MD, MPH
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
Drs. Mascitelli and Pezzetta suggest that abnormal glucose metabolism might be responsible for the null association that we observed between C-reactive protein levels and risk for colorectal cancer. We conducted an analysis excluding 681 women who reported a history of diabetes mellitus at baseline from our study sample, and the associations between C-reactive protein and risk for colorectal cancer did not appreciably change. The multivariable hazard ratios and their corresponding 95% CIs according to cutoff points for C-reactive protein were 0.74 (95% CI, 0.49 to 1.11) for the category of 1 to 3 mg/L and 0.66 (CI, 0.42 to 1.03) for the category of greater than 3 mg/L (P = 0.12 for trend), compared with the category of less than 1 mg/L. These data suggest that our findings are unlikely to be explained by confounding by diabetes mellitus.
Shumin M. Zhang, MD, ScD
Paul M Ridker, MD, MPH
Brigham and Women's Hospital; Boston, MA 02215
Article and Author Information
-
Potential Financial Conflicts of Interest: None disclosed.
